A Study of Chemotherapy Plus ddI or ddC in the Treatment of AIDS-Related Kaposi's Sarcoma
Status:
Completed
Trial end date:
1996-09-01
Target enrollment:
Participant gender:
Summary
To determine the toxicity and response to treatment with cytotoxic chemotherapy using
doxorubicin (Adriamycin), bleomycin, and vincristine (DBV) for advanced AIDS-related Kaposi's
sarcoma in combination with either didanosine (ddI) or zalcitabine (dideoxycytidine; ddC).
AIDS patients with extensive Kaposi's sarcoma require treatment with effective cytotoxic
agents to reduce the tumor burden, and they also require treatment with other possibly
effective antiretroviral agents such as ddI or ddC to ameliorate (delay) the development of
opportunistic infections.
Phase:
Phase 1
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)